JNJ · Johnson & Johnson · Financials
$255.56
+2.28 (+0.90%)
At close · Oct 16
Return incl. dividend (before tax)
Market Cap
$615.87B
Shares
2.41B
Volume · Oct 16
6.6M
Avg daily vol (3M)
7.08M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$94.19B
+6%
FY2025
Net Income
$26.8B
+90.6%
FY2025
Gross Margin
67.88%
-1.2pp
FY2025
Diluted EPS
$11.03
+90.5%
FY2025
Operating Cash Flow
$24.53B
+1.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $101B – $101.4B | $97.93B | $94.19B | $88.82B | $85.16BG | $79.99BG | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B | — | — | — | — | — | — | — | — | — | |
| — | $31.43B | $30.26B | $27.47B | $26.55B | $24.6B | $23.4B | $28.43B | $27.56B | $27.09B | $25.44B | $21.79B | $21.54B | $22.75B | $22.34B | $21.66B | $20.36B | $18.79B | $18.45B | $18.51B | $17.75B | |
| — | $66.5B | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.5B | $54.49B | $51.01B | $50.1B | $48.54B | $51.59B | $48.97B | $45.57B | $44.67B | $42.8B | $43.45B | $45.24B | $43.34B | |
| — | — | 67.88% | 69.07% | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.72% | 69.69% | — | — | — | — | — | — | — | — | — | |
| — | $548M | $109M | $1.84B | $483M | $0 | $0 | $12.16B | $11.36B | $10.78B | $10.59B | $9.14B | $9.05B | $8.49B | $8.18B | $7.67B | $7.55B | $6.84B | $6.99B | $7.58B | $7.68B | |
| — | $25.14B | $23.68B | $22.87B | $21.51B | $20.25B | $20.12B | $22.08B | $22.18B | $22.54B | $21.52B | $20.07B | $21.2B | $21.95B | $21.83B | $20.87B | $20.97B | $19.42B | $19.8B | $21.49B | $20.45B | |
| — | $4.6B | $4.6B | $4.5B | $4.5B | $3.9B | $4.2B | $4.7B | $4.5B | $4.4B | $3B | $1.2B | $1.2B | $1.4B | $1.4B | $1.15B | $852M | $748M | $0 | $0 | $678M | |
| — | $7.75B | $7.5B | $7.34B | $7.49B | $6.97B | $7.39B | $7.23B | $7.01B | $6.93B | $5.64B | $3.75B | $3.75B | $3.9B | $4.1B | $3.67B | $3.16B | $2.94B | $2.77B | $2.83B | $2.78B | |
| — | $213M | $228M | $234M | $489M | $275M | $209M | $247M | $266M | $251M | $309M | $491M | $509M | $0 | $0 | $0 | $569M | $0 | $1.07B | $0 | $745M | |
| — | $21.77B | — | — | — | — | — | — | — | — | — | — | — | $21.59B | $16.41B | $14.96B | $13.77B | $17.7B | $16.58B | — | — | |
| — | $25.54B | — | — | — | — | — | — | — | — | — | — | — | $25.49B | $20.52B | $18.62B | $16.92B | $20.64B | $19.36B | — | — | |
| — | $1.01B | $971M | $755M | $772M | $276M | $183M | $201M | $318M | $1.01B | $934M | $726M | $552M | $533M | $482M | $532M | $571M | $455M | $451M | $435M | $296M | |
| — | $912M | $1.06B | $1.33B | $1.26B | $490M | $53M | $111M | $357M | $611M | $385M | $368M | $128M | $67M | $74M | $64M | $91M | $107M | $90M | $361M | $452M | |
| — | -$630M | $7.21B | -$4.69B | -$6.63B | -$810M | -$526M | -$2.9B | -$2.53B | -$1.41B | $42M | -$210M | $2.06B | $70M | -$2.5B | -$1.63B | -$2.74B | $768M | $526M | $1.02B | -$534M | |
| — | $25.2B | $32.58B | $16.69B | $15.06B | $19.36B | $19.18B | $16.5B | $17.33B | $18B | $17.67B | $19.8B | $19.2B | $20.56B | $15.47B | $13.78B | $12.36B | $16.95B | $15.76B | $16.93B | $13.28B | |
| — | $4.16B | $5.78B | $2.62B | $1.74B | $2.99B | $1.38B | $1.78B | $2.21B | $2.7B | $16.37B | $3.26B | $3.79B | $4.24B | $1.64B | $3.26B | $2.69B | $3.61B | $3.49B | $3.98B | $2.71B | |
| — | $21.04B | $26.8B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.3B | $1.3B | $16.54B | $15.41B | $16.32B | $13.83B | $10.85B | $9.67B | $13.33B | $12.27B | $12.95B | $10.58B | |
| — | — | 28.46% | 15.84% | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.7% | 23.01% | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | -$339M | $0 | $0 | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $8.46B | $16.78B | $10.68B | $7.57B | $12.86B | — | — | — | |
| USD/shares | — | $8.73 | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.72 | $5.70 | $0.48 | $6.04 | $5.56 | $5.80 | $4.92 | $3.94 | $3.54 | $4.85 | $4.45 | $4.62 | $3.67 |
| USD/shares | $11.05 – $11.15* | $8.61 | $11.03 | $5.79 | $13.72G | $6.73G | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 | $5.48 | $5.70 | $4.81 | $3.86 | $3.49 | $4.78 | $4.40 | $4.57 | $3.63 |
| shares | — | — | 2.41B | 2.41B | 2.53B | 2.63B | 2.63B | 2.63B | 2.65B | 2.68B | 2.69B | 2.74B | 2.77B | 2.82B | 2.81B | 2.75B | 2.74B | 2.75B | 2.76B | 2.8B | 2.88B |
| shares | — | — | 2.43B | 2.43B | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B | 2.75B | 2.79B | 2.81B | 2.86B | 2.88B | 2.81B | 2.78B | 2.79B | 2.79B | 2.84B | 2.91B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $102.68B in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Latest reported total
USD 49,000,000,000
As of Jun 28, 2026
Tracked instruments
0
Loans, facilities and note series
Annual baseline
—
Latest approved annual total
Reported total debt history
| As of | Reported label | Amount | Source |
|---|---|---|---|
| 2026-06-28 | The Company's debt position | USD 49,000,000,000 |
10-Q filed 2026-07-23
The Company's debt position was $49.0 billion as of June 28, 2026, as compared to $50.8 billion the same period a year ago. |
| 2026-03-29 | notes payable and long-term debt | USD 55,000,000,000 |
10-Q filed 2026-04-22
As of March 29, 2026, the Company had cash, cash equivalents and marketable securities of approximately $22.1 billion and had approximately $55.0 billion of notes payable and long-term debt for a net debt position of $32.9 billion as compared to the prior year fiscal first quarter net debt position of $13.5 billion. |
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent debt carrying amount | 2026-06-28 | USD 37,344,000,000 | 10-Q filed 2026-07-23 |
| Short-term borrowings | 2026-06-28 | USD 11,692,000,000 | 10-Q filed 2026-07-23 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
2 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
6.58×
Peer median 7.12×
EV/EBIT
—
P/E (TTM)
29.68×
Peer median 40.55×
Peer medians compare against the 7 similar-size Drug Manufacturers - General companies (of 15 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $60,401,000,000 | $56,964,000,000 | $54,759,000,000 | $52,563,000,000 | $51,680,000,000 | $45,175,000,000 | $42,198,000,000 | $40,734,000,000 |
| MedTech | $33,792,000,000 | $31,857,000,000 | $30,400,000,000 | $27,427,000,000 | $27,060,000,000 | $22,959,000,000 | $25,963,000,000 | $26,994,000,000 |
| Consumer | — | — | — | $14,953,000,000 | — | $14,450,000,000 | $13,898,000,000 | $13,853,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $53,752,000,000 | $50,302,000,000 | $46,444,000,000 | $41,981,000,000 | $40,640,000,000 | $43,133,000,000 | $42,097,000,000 | $41,884,000,000 |
| Europe | $21,535,000,000 | $20,212,000,000 | $20,410,000,000 | $20,664,000,000 | $20,595,000,000 | $18,980,000,000 | $18,466,000,000 | $18,753,000,000 |
| Asia Pacific Africa | $14,031,000,000 | $13,593,000,000 | $13,756,000,000 | $13,237,000,000 | $13,578,000,000 | $15,136,000,000 | $15,555,000,000 | $14,831,000,000 |
| Western Hemisphere Excluding US | $4,875,000,000 | $4,714,000,000 | $4,549,000,000 | $4,108,000,000 | $3,927,000,000 | $5,335,000,000 | $5,941,000,000 | $6,113,000,000 |
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| OTC | $6,031,000,000 | $5,627,000,000 | $5,221,000,000 | $4,444,000,000 | $4,334,000,000 | $4,126,000,000 |
| Skin Health Beauty | $4,352,000,000 | $4,541,000,000 | $4,450,000,000 | $4,593,000,000 | $4,382,000,000 | $4,200,000,000 |
| Oral Care | $1,505,000,000 | $1,645,000,000 | $1,641,000,000 | $1,528,000,000 | $1,555,000,000 | $1,531,000,000 |
| Baby Care | $1,461,000,000 | $1,566,000,000 | $1,517,000,000 | $1,675,000,000 | $1,858,000,000 | $1,916,000,000 |
| Womens Health | $904,000,000 | $917,000,000 | $901,000,000 | $986,000,000 | $1,049,000,000 | $1,050,000,000 |
| Wound Care and Other | $700,000,000 | $739,000,000 | $720,000,000 | $671,000,000 | $675,000,000 | $779,000,000 |
Key facts
CIK
200406
CUSIP
478160104
13F (30d)
958 filings
895 filers
Visit website
Investor relations